Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ResMed Inc. (RMD) vs UnitedHealth Group Inc (UNH) Price & Performance

ResMed Inc.Trade
UnitedHealth Group IncTrade

Price performance (Past 24H)

Key statistics

ResMed Inc. vs UnitedHealth Group Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while UnitedHealth Group Inc trades at $394.37 (market cap $359.79B). The key difference: UnitedHealth Group Inc is far larger — about 11.3× ResMed Inc.'s market cap, and UnitedHealth Group Inc pays the higher dividend (2.32%). Which is the better fit depends on your goals.

RMDUNH
Market Cap
$31.89B$359.79B
Sector
HealthHealth
52-Week High
$283.28$436.35
52-Week Low
$182.82$259.02
Enterprise Value
$31.24B$401.65B
Dividend Yield
1.19%2.32%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ResMed Inc.

ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.

The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.

UnitedHealth Group Inc

UnitedHealth Group (UNH) trades at $393.06, down 1.03% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported revenue of $447.57B in 2025, with net income of $12.06B, and has beaten EPS estimates in recent quarters. Recent news highlights strategic moves to reduce pediatric prior authorizations and ongoing shareholder returns via dividends and buybacks.

The outlook for UNH is positive, driven by aging demographics, Medicare growth, and operational efficiencies, though risks include regulatory scrutiny and margin pressures. With 82.7% of analysts rating it a buy and a consensus price target of $475.47, the stock presents a compelling opportunity for long-term investors seeking exposure to healthcare stability and dividend growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD

About UnitedHealth Group Inc

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to 50 million members globally, including 5 million outside the U.S. at the end of 2021. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.

Read more on UNH